Effect of interleukin-1β on the release of substance P from rat isolated spinal cord

https://doi.org/10.1016/0014-2999(95)00845-4Get rights and content

Abstract

Superfusion of rat spinal cord slices with rat interleukin-1β resulted in a significant enhancement of electrically evoked substance P-like immunoreactivity with a maximal effect (> 2-fold increase) at 0.1 ng/ml, whereas higher concentration (10–50 ng/ml) of the cytokine inhibited (≈ 50%) the release of the neuropeptide. Interleukin-1β (0.1 ng/ml) potentiation of substance P-like immunoreactivity release was abrogated by co-perfusion with interleukin-1 receptor antagonist (10–100 ng/ml) or with indomethacin (1 μM). Superfusion of spinal cord with interleukin-1β inhibited electrically evoked calcitonin gene-related peptide-like immunoreactivity release. Modulation of substance P-like immunoreactivity release from the spinal cord by interleukin-1β may represent a mechanism responsible for the hyperalgesic action of the cytokine characteristic of the inflammatory response.

References (27)

  • W.A. Banks et al.

    Blood-borne interleukin-1α is transported across the endothelial blood-spinal cord barrier of mice

    J. Physiol. (London)

    (1994)
  • A.J. Davis et al.

    The involvement of bradikinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat

    Br. J. Pharmacol.

    (1994)
  • S.P. Eisenberg et al.

    Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist

    Nature

    (1990)
  • Cited by (77)

    • Involvement of microglial cells in the antinociceptive effects of metamizol in a mouse model of neuropathic pain

      2018, Pharmacology Biochemistry and Behavior
      Citation Excerpt :

      The chosen pronociceptive factors undoubtedly play an important role in the process of nociception (Mika et al., 2013; Popiolek-Barczyk and Mika, 2016). IL-1β is known to be strongly activated upon neural damage (Hopkins and Rothwell, 1995; Mika et al., 2008), and intrathecal administration of IL-1β induces hypersensitivity in rats (Malcangio et al., 1996; Mika et al., 2008; Obreja et al., 2002; Oprée, 2000). Moreover, IL-1β is capable of inducing secretion of other pronociceptive cytokines, including CCL2.

    • Maraviroc reduces neuropathic pain through polarization of microglia and astroglia - Evidence from in vivo and in vitro studies

      2016, Neuropharmacology
      Citation Excerpt :

      Overproduction of IL-1β, IL-18 and IL-6 is implicated in the pathophysiological changes that occur during different disease states, including neuropathic pain (Dinarello, 1996; Okamoto et al., 2001; Braddock and Quinn, 2004; Miyoshi et al., 2008; Ren and Torres, 2009; Pilat et al., 2015, 2016; Rojewska et al., 2016). Moreover, intrathecal administration of both IL-1β and IL-18 cause allodynia and hyperalgesia in rats (Malcangio et al., 1996; Mika et al., 2008; Miyoshi et al., 2008). In contrast, IL-1RA (Malcangio et al., 1996; Mika et al., 2008; Pilat et al., 2015) and IL-18BP promote antiallodynic activity (Miyoshi et al., 2008; Pilat et al., 2016) under conditions of neuropathy.

    • Fibromyalgia and cytokines

      2014, Immunology Letters
      Citation Excerpt :

      IL-1 and TNF act synergically and induce the synthesis of adhesion molecules by endothelial cells, which are essential in neutrophil recruitment to the inflammation site. IL-1 alone, or in combination with TNF increases prostaglandin synthesis (i.e. PGE2) and regulates substance P gene expression decreasing pain threshold in peripheral nerves [17]. Patients injected with IL-1 develop fever, headache, myalgia and arthralgia and this is reduced by the administration of COX inhibitors [18] and also such symptoms are very often found in fibromyalgia patients.

    • Importance of glial activation in neuropathic pain

      2013, European Journal of Pharmacology
    View all citing articles on Scopus
    1

    Present address: Department of Pharmacology, Queen Mary and Westfield College, Mile End Road, London E1 4NS, UK.

    2

    Present address: Department of Pharmacology, The Medical School, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.

    View full text